Lana Kandalaft

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil

50 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2006 | 2003 |
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B., Navarro Rodrigo B., Décombaz L., Wang H., Ercolano G., Ahmed R., Lozano L.E., Ianaro A., Derré L., Valerio M. et al., 2019/10/10. Journal for immunotherapy of cancer, 7 (1) p. 257. Peer-reviewed.
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft L.E., Odunsi K., Coukos G., 2019/09/20. Journal of clinical oncology, 37 (27) pp. 2460-2471. Peer-reviewed.
Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.
Digklia A., Duran R., Homicsko K., Kandalaft L.E., Hocquelet A., Orcurto A., Coukos G., Denys A., 2019/09. Cardiovascular and interventional radiology, 42 (9) pp. 1221-1229. Peer-reviewed.
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
Bassani-Sternberg Michal, Digklia Antonia, Huber Florian, Wagner Dorothea, Sempoux Christine, Stevenson Brian J., Thierry Anne-Christine, Michaux Justine, Pak HuiSong, Racle Julien et al., 2019/08/08. Frontiers in Immunology, 10. Peer-reviewed.
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Jreige M., Letovanec I., Chaba K., Renaud S., Rusakiewicz S., Cristina V., Peters S., Krueger T., de Leval L., Kandalaft L.E. et al., 2019/08. European journal of nuclear medicine and molecular imaging, 46 (9) pp. 1859-1868. Peer-reviewed.
Rational combinations of immunotherapy with radiotherapy in ovarian cancer.
Herrera F.G., Irving M., Kandalaft L.E., Coukos G., 2019/08. The Lancet. Oncology, 20 (8) pp. e417-e433. Peer-reviewed.
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F. et al., 2019/06/10. Cancer cell, 35 (6) pp. 885-900.e10. Peer-reviewed.
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
Bol K.F., Schreibelt G., Rabold K., Wculek S.K., Schwarze J.K., Dzionek A., Teijeira A., Kandalaft L.E., Romero P., Coukos G. et al., 2019/04/18. Journal for immunotherapy of cancer, 7 (1) p. 109. Peer-reviewed.
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera F.G., Valerio M., Berthold D., Tawadros T., Meuwly J.Y., Vallet V., Baumgartner P., Thierry A.C., De Bari B., Jichlinski P. et al., 2019/02/01. International journal of radiation oncology, biology, physics, 103 (2) pp. 320-334. Peer-reviewed.
IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
Mookerjee Ananda, Graciotti Michele, Kandalaft Lana E., 2019/01/04. Cancers, 11 (1) p. 40.
Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.
Mookerjee A., Graciotti M., Kandalaft L.E., 2019..
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
Yakkala C., Chiang C.L., Kandalaft L., Denys A., Duran R., 2019. Frontiers in immunology, 10 p. 2283. Peer-reviewed.
Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.
Mastelic-Gavillet B., Balint K., Boudousquie C., Gannon P.O., Kandalaft L.E., 2019. Frontiers in immunology, 10 p. 766. Peer-reviewed.
In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang C.L., Kandalaft L.E., 2018/12. Cancer treatment reviews, 71 pp. 88-101. Peer-reviewed.
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
Martin Lluesma S., Graciotti M., Chiang C.L., Kandalaft L.E., 2018/11/23. Vaccines, 6 (4). Peer-reviewed.
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Neubert N.J., Schmittnaegel M., Bordry N., Nassiri S., Wald N., Martignier C., Tillé L., Homicsko K., Damsky W., Maby-El Hajjami H. et al., 2018/04/11. Science translational medicine, 10 (436). Peer-reviewed.
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y., Hu J., Wang Y., Peng X., Min J., Wang J., Matthaiou E., Cheng Y., Sun K., Tong X. et al., 2018/02. European journal of cancer, 90 pp. 111-121. Peer-reviewed.
A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.
Mookerjee A., Graciotti M., Kandalaft L., 2018. BioImpacts, 8 (3) pp. 211-221. Peer-reviewed.
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.
Tsoutsou P.G., Zaman K., Martin Lluesma S., Cagnon L., Kandalaft L., Vozenin M.C., 2018. Frontiers in oncology, 8 p. 609. Peer-reviewed.
The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
Graciotti M., Berti C., Klok H.A., Kandalaft L., 2017/06/19. Journal of translational medicine, 15 (1) p. 142. Peer-reviewed.
Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.
Bassani-Sternberg M., Chong C., Guillaume P., Solleder M., Pak H., Gannon P.O., Kandalaft L.E., Coukos G., Gfeller D., 2017. PLoS Computational Biology, 13 (8) pp. e1005725. Peer-reviewed.
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Martin Lluesma S., Wolfer A., Harari A., Kandalaft L.E., 2016/05/03. Biomedicines, 4 (2) pp. NA. Peer-reviewed.
Opportunities in immunotherapy of ovarian cancer.
Coukos G., Tanyi J., Kandalaft L.E., 2016/04. Annals of oncology, 27 Suppl 1 pp. i11-i15. Peer-reviewed.
Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.
Zsiros E., Dangaj D., June C.H., Kandalaft L.E., Coukos G., 2016. Oncoimmunology, 5 (5) pp. e1062210. Peer-reviewed.
Personalized approaches to active immunotherapy in cancer
Ophir Eran, Bobisse Sara, Coukos George, Harari Alexandre, Kandalaft Lana E., 2016/01. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1865 (1) pp. 72-82. Peer-reviewed.
Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.
Yan X., Hu Z., Feng Y., Hu X., Yuan J., Zhao S.D., Zhang Y., Yang L., Shan W., He Q. et al., 2015. Cancer Cell, 28 (4) pp. 529-540. Peer-reviewed.
Potential approaches for more successful dendritic cell-based immunotherapy.
Chiang C.L., Balint K., Coukos G., Kandalaft L.E., 2015. Expert Opinion On Biological Therapy, 15 (4) pp. 569-582. Peer-reviewed.
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.
Zsiros E., Duttagupta P., Dangaj D., Li H., Frank R., Garrabrant T., Hagemann I.S., Levine B.L., June C.H., Zhang L. et al., 2015. Clinical Cancer Research, 21 (12) pp. 2840-2850. Peer-reviewed.
Whole Tumor Antigen Vaccines: Where Are We?
Chiang C.L.L., Coukos G., Kandalaft L.E., 2015. Vaccines, 3 (2) pp. 344-372. Peer-reviewed.
Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E., Tanyi J., Balint K., Kandalaft L.E., 2014/09. Current opinion in oncology, 26 (5) pp. 492-500. Peer-reviewed.
A dendritic cell vaccine pulsed with autologous hypochlorous Acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
Chiang C.L., Kandalaft L.E., Tanyi J., Hagemann A.R., Motz G.T., Svoronos N., Montone K., Mantia-Smaldone G.M., Smith L., Nisenbaum H.L. et al., 2013. Clinical Cancer Research, 19 (17) pp. 4801-4815. Peer-reviewed.
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.
Kandalaft L.E., Chiang C.L., Tanyi J., Motz G., Balint K., Mick R., Coukos G., 2013. Journal of Translational Medicine, 11 p. 149.
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.
Kandalaft L.E., Powell D.J., Chiang C.L., Tanyi J., Kim S., Bosch M., Montone K., Mick R., Levine B.L., Torigian D.A. et al., 2013. Oncoimmunology, 2 (1) pp. e22664.
A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.
Kandalaft L.E., Powell D.J., Coukos G., 2012. Journal of Translational Medicine, 10 p. 157.
Conference scene: Immune signatures in the tumor and beyond.
Kandalaft L.E., Kalos M., Melief C.J., Speiser D.E., Coukos G., 2012. Immunotherapy, 4 (8) pp. 761-772.
Clinical translation section: accelerating the pace from bench to bedside.
Kandalaft L.E., Coukos G., 2011/07/21. Journal of translational medicine, 9 p. 116. Peer-reviewed.
Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.
Chiang C.L., Kandalaft L.E., Coukos G., 2011. International Reviews of Immunology, 30 (2-3) pp. 150-182.
Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.
Kandalaft L.E., Motz G.T., Busch J., Coukos G., 2011. Current Topics In Microbiology and Immunology, 344 pp. 129-148.
Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.
Chiang C.L., Hagemann A.R., Leskowitz R., Mick R., Garrabrant T., Czerniecki B.J., Kandalaft L.E., Powell D.J., Coukos G., 2011. Plos One, 6 (12) pp. e28732.
Immunotherapy for ovarian cancer: what's next?
Kandalaft L.E., Powell D.J., Singh N., Coukos G., 2011. Journal of Clinical Oncology, 29 (7) pp. 925-933.
Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.
Chiang C.L., Maier D.A., Kandalaft L.E., Brennan A.L., Lanitis E., Ye Q., Levine B.L., Czerniecki B.J., Powell D.J., Coukos G., 2011. Journal of Translational Medicine, 9 p. 198.
Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
Kandalaft L.E., Motz G.T., Duraiswamy J., Coukos G., 2011. Cancer Metastasis Reviews, 30 (1) pp. 141-151.
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.
Kandalaft L.E., Singh N., Liao J.B., Facciabene A., Berek J.S., Powell D.J., Coukos G., 2010. Gynecologic Oncology, 116 (2) pp. 222-233.
Endothelin B receptor, a new target in cancer immune therapy.
Kandalaft L.E., Facciabene A., Buckanovich R.J., Coukos G., 2009. Clinical Cancer Research, 15 (14) pp. 4521-4528.
Differentially expressed nucleolar transforming growth factor-beta1 target (DENTT) exhibits an inhibitory role on tumorigenesis.
Kandalaft L.E., Zudaire E., Portal-Núñez S., Cuttitta F., Jakowlew S.B., 2008/06. Carcinogenesis, 29 (6) pp. 1282-1289. Peer-reviewed.
Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung.
Sakagami M., Omidi Y., Campbell L., Kandalaft L.E., Morris C.J., Barar J., Gumbleton M., 2006/02. Pharmaceutical research, 23 (2) pp. 270-279. Peer-reviewed.
Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers.
Siccardi D., Kandalaft L.E., Gumbleton M., McGuigan C., 2003/12. The Journal of pharmacology and experimental therapeutics, 307 (3) pp. 1112-1119. Peer-reviewed.
Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures.
Campbell L., Abulrob A.N., Kandalaft L.E., Plummer S., Hollins A.J., Gibbs A., Gumbleton M., 2003/01. The Journal of pharmacology and experimental therapeutics, 304 (1) pp. 441-452. Peer-reviewed.
Unicentre - CH-1015 Lausanne
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University